Glycogen Synthase Kinase-3 Inhibition by CHIR99021 Promotes Alveolar Epithelial Cell Proliferation and Lung Regeneration in the Lipopolysaccharide-Induced Acute Lung Injury Mouse Model

Raquel Fernandes,Catarina Barbosa-Matos,Caroline Borges-Pereira,Ana Luísa Rodrigues Toste de Carvalho,Sandra Costa
DOI: https://doi.org/10.3390/ijms25021279
IF: 5.6
2024-01-20
International Journal of Molecular Sciences
Abstract:Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that currently lacks effective clinical treatments. Evidence highlights the potential role of glycogen synthase kinase-3 (GSK-3) inhibition in mitigating severe inflammation. The inhibition of GSK-3α/β by CHIR99021 promoted fetal lung progenitor proliferation and maturation of alveolar epithelial cells (AECs). The precise impact of CHIR99021 in lung repair and regeneration during acute lung injury (ALI) remains unexplored. This study intends to elucidate the influence of CHIR99021 on AEC behaviour during the peak of the inflammatory phase of ALI and, after its attenuation, during the repair and regeneration stage. Furthermore, a long-term evaluation was conducted post CHIR99021 treatment at a late phase of the disease. Our results disclosed the role of GSK-3α/β inhibition in promoting AECI and AECII proliferation. Later administration of CHIR99021 during ALI progression contributed to the transdifferentiation of AECII into AECI and an AECI/AECII increase, suggesting its contribution to the renewal of the alveolar epithelial population and lung regeneration. This effect was confirmed to be maintained histologically in the long term. These findings underscore the potential of targeted therapies that modulate GSK-3α/β inhibition, offering innovative approaches for managing acute lung diseases, mostly in later stages where no treatment is available.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The paper primarily explores the effects of the GSK-3 (glycogen synthase kinase-3) inhibitor CHIR99021 in a mouse model of acute lung injury (ALI). Specifically, the study aims to address the following key questions: 1. **Evaluate the impact of CHIR99021 on acute lung injury**: The study assesses the effects of CHIR99021 on lung tissue damage, immune cell infiltration, and apoptosis at different time points in an LPS (lipopolysaccharide)-induced mouse ALI model. 2. **Explore whether CHIR99021 can promote the proliferation and regeneration of alveolar epithelial cells (AECs)**: The research focuses on whether CHIR99021 can promote the proliferation of different types of alveolar epithelial cells (including AEC type I and AEC type II cells), thereby facilitating the repair and regeneration of lung tissue. 3. **Analyze the impact of CHIR99021 on the inflammatory response**: Although previous studies have shown that GSK-3 inhibition can alleviate the inflammatory response, this study aims to investigate whether CHIR99021 can directly regulate the inflammatory response in the ALI model. In summary, the core objective of this paper is to explore the specific effects of CHIR99021, as a GSK-3 inhibitor, on lung injury repair and regeneration in an acute lung injury model, and to further understand its possible mechanisms of action. The study particularly emphasizes the potential application of CHIR99021 in the late treatment stage, providing a new perspective for the future development of therapeutic approaches for acute lung diseases such as acute respiratory distress syndrome (ARDS).